NewLimit
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale. All correspondence from NewLimit will come from an @NewLimit.com email address.www.newlimit.com
5
MENTIONS
2
EPISODES
2
PODCASTS
Search complete. 5 mentions across 2 episodes found for "NewLimit".
Sep 10, 2026
Brian ArmstrongGUEST
So a lot of it is it's, uh, gathering information.
Brian ArmstrongGUEST
Um, and so you could, you could think of it like, um, it's venture firms doing research compiling from, uh, paywalled data, or it's recruiters, uh, who need to scrape data from, um, from LinkedIn.
Brian ArmstrongGUEST
It's...
Brian ArmstrongGUEST
Oftentimes, it's actually agents talking to other agents that are specialized in some, in some way and getting source data from them, almost like a tool call that's happening.
Ashlee VanceHOST
Um, Sam Altman's funded RetroBio is, is doing some work in this area.
Ashlee VanceHOST
New Limit, funded by Bryan Armstrong and others also here.
Ashlee VanceHOST
So y- and, and there's more players, but we're talking billions upon billions of dollars have gone into this.
Ashlee VanceHOST
Um, yeah, and I, you know, when you and I have talked, I think you're, I don't know if it's fair to call you a skeptic.
10 MINS LATER
Alex ColvilleGUEST
And I'm like, no, pretty much everything in the aging field, even reprogramming with these billions of dollars, is totally underfunded because reprogramming could be tailored to each individual cell type or, uh, tissue in your body.
Alex ColvilleGUEST
Uh, and I remember Jacob Kimmel, uh, who-
Ashlee VanceHOST
From New Limit
Alex ColvilleGUEST
...